[Cancers of the breast at metastatic high-risk: prediction of survival by steroidal receptors].
From 1982 to 1985, 279 patients with locally advanced breast cancer have been treated with induction chemotherapy, adjusted loco-regional treatment (surgery and/or radiotherapy) and adjuvant chemotherapy with or without immunostimulation. Overall and relapse free survivals are better for tumors with estrogen and progesterone receptors (EPR). For these patients, we may hope that tumoral reduction with hormonotherapy would get the same overall and relapse-free survivals as induction chemotherapy.
Mauriac
L
L
Fondation Bergonié, Bordeaux, France.
Durand
M
M
Chauvergne
J
J
David
M
M
Wafflart
J
J
D001943:Breast Neoplasms / Q000032:analysis / Q000188:drug therapy / Q000401:mortality* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D012307:Risk Factors
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
Les cancers du sein à haut risque métastatique: prédiction de la survie par les récepteurs stéroïdiens.